Rafael (RFL) 10-K 4 Oct 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Oct. 02, 2019	Jan. 31, 2019
Entity Registrant Name	Rafael Holdings, Inc.
Entity Central Index Key	0001713863
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Document Type	10-K
Document Period End Date	Jul. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Ex Transition Period	false
Entity Emerging Growth Company	true
Entity Public Float			$ 96,000
Entity File Number	000-55863
Entity Shell Company	false
Entity Incorporation State country code	DE
Class A common stock
Entity Common Stock, Shares Outstanding		787,163
Class B common stock
Entity Common Stock, Shares Outstanding		14,997,251

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 12,024	$ 15,803
Trade accounts receivable, net of allowance for doubtful accounts of $122 and $82 at July 31, 2019 and 2018, respectively	450	287
Marketable securities		24,701
Due from Rafael Pharmaceuticals	280	3,300
Prepaid expenses and other current assets	507	421
Total current assets	13,261	44,512
Property and equipment, net	48,733	50,113
Investments - Rafael Pharmaceuticals	70,018	13,300
Investments - Other Pharmaceuticals	2,000	2,000
Investments - Hedge Funds	5,125	4,218
Deferred income tax assets, net	19
In-process research and development and patents	1,575	1,651
Other assets	1,412	1,126
TOTAL ASSETS	142,143	116,920
CURRENT LIABILITIES
Trade accounts payable	795	367
Accrued expenses	605	500
Other current liabilities	27	24
Total current liabilities	1,427	891
Due to Related Parties	65	276
Convertible debt, net of discount of $54 - Related Party	14,946
Other liabilities	292	188
Accrued interest on convertible note - Related Party	649
TOTAL LIABILITIES	17,379	1,355
COMMITMENTS AND CONTINGENCIES
EQUITY
Additional paid-in capital	112,898	103,636
Accumulated deficit	(5,840)	(1,108)
Accumulated other comprehensive income	3,784	4,043
Total equity attributable to Rafael Holdings, Inc.	110,981	106,697
Noncontrolling interests	13,783	8,868
TOTAL EQUITY	124,764	115,565
TOTAL LIABILITIES AND EQUITY	142,143	116,920
Class A common stock
EQUITY
Common stock value	8	8
Total equity attributable to Rafael Holdings, Inc.	8	8
TOTAL EQUITY	8	8
Class B common stock
EQUITY
Common stock value	131	118
Total equity attributable to Rafael Holdings, Inc.	131	118
TOTAL EQUITY	$ 131	$ 118

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Allowance for doubtful accounts	$ 122	$ 82
Convertible debt, net of discount	$ 54
Class A common stock
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	787,163	787,163
Common stock, shares outstanding	787,163	787,163
Class B common stock
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	13,142,502	11,762,346
Common stock, shares outstanding	13,142,502	11,762,346

Consolidated and Combined State

Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
REVENUES:
Rental – Third Party	$ 1,452	$ 1,275
Rental – Related Party	2,125	2,223
Parking	874	873
Other – Related Party	480
Total Revenue	4,931	4,371
COSTS AND EXPENSES:
Selling, general and administrative	8,821	5,519
Research and development	1,027	995
Depreciation and amortization	1,779	1,698
Loss from operations	(6,696)	(3,841)
Interest income, net	469	16
Net gains resulting from foreign exchange transactions	47	32
Net loss on equity investments		(104)
Gain on sales of marketable securities	330	12
Unrealized gain on Investments – Hedge Funds	907
Gain on disposal of bonus shares		246
Loss before income taxes	(4,943)	(3,639)
Benefit from (provision for) income taxes	19	(8,437)
Net Loss	(4,924)	(12,076)
Net loss attributable to noncontrolling interests	(231)	(427)
Net loss attributable to Rafael Holdings, Inc.	(4,693)	(11,649)
OTHER COMPREHENSIVE LOSS
Net Loss	(4,924)	(12,076)
Unrealized loss on marketable securities		(308)
Unrealized gain on available-for-sale securities		1,869
Foreign currency translation adjustments	298	166
Total Comprehensive Loss	(4,626)	(10,349)
Comprehensive income (loss) attributable to noncontrolling interests	173	(107)
Total Comprehensive Loss attributable to Rafael Holdings, Inc.	$ (4,453)	$ (10,456)
Loss per share attributable to Rafael Holdings, Inc. common stockholders:
Basic and diluted	$ (0.35)	$ (0.93)
Weighted average number of shares used in calculation of loss per share:
Basic and diluted	13,275,239	12,485,000

Consolidated and Combined Sta_2

Consolidated and Combined Statements of Equity - USD ($) $ in Thousands	Common Stock, Series A	Common Stock, Series B	Group Equity	Additional Paid - in Capital	Accumulated Deficit	Accumulated other comprehensive income	Noncontrolling interests	Total
BALANCE at Jul. 31, 2017			$ 50,427			$ 2,316	$ 9,335	$ 62,078
Net loss			(10,541)		(1,108)		(427)	(12,076)
Stock-based compensation				51				51
Stock-based compensation, Shares		7,511
Unrealized loss on available-for-sale securities							(40)	(40)
Non-cash compensation related to the distribution of bonus shares						1,561		1,561
Incorporation of Company, capital contribution from IDT and share distribution on Spin-Off	$ 8	$ 118	(39,886)	103,485				63,725
Incorporation of Company, capital contribution from IDT and share distribution on Spin-Off, shares	787,163	11,754,835
Indemnification from IDT for settled lawsuit				100				100
Foreign currency translation adjustment						166		166
BALANCE at Jul. 31, 2018	$ 8	$ 118		103,636	(1,108)	4,043	8,868	115,565
BALANCE, SHARES at Jul. 31, 2018	787,163	11,754,835
Net loss					(4,693)		(231)	(4,924)
Adoption effect of ASU 2016-01					(39)	39
Stock-based compensation		$ 1		264				265
Stock-based compensation, Shares		74,637
Stock options exercised		$ 0		190				190
Stock options exercised, shares		38,710
Sale of Class B Common Shares		$ 12		8,630				8,642
Sale of Class B Common Shares, Shares		1,254,200
Stock-based compensation to Board of Directors		$ 0		107				107
Stock-based compensation to Board of Directors, shares		12,609
Debt Discount on convertible debt				71				71
Capital contribution for noncontrolling interest							4,587	4,587
Foreign currency translation adjustment						(298)		(298)
BALANCE at Jul. 31, 2019	$ 8	$ 131		$ 112,898	$ (5,840)	$ 3,784	$ 13,783	$ 124,764
BALANCE, SHARES at Jul. 31, 2019	787,163	13,142,502

Consolidated and Combined Sta_3

Consolidated and Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Operating activities
Net loss	$ (4,924)	$ (12,076)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,779	1,698
Deferred income taxes	(19)	8,859
Interest income on Rafael Pharmaceuticals Series D Convertible Note	(848)
Interest income	(37)
Net realized and unrealized gain on sale of marketable securities	(330)
Net realized and unrealized gain on Investments - Hedge Funds	(907)
Provision for doubtful accounts	122
Non-cash compensation	372	104
Amortization of debt discount	17	657
Realized gain on disposal of bonus shares		(246)
Loss on disposal of fixed assets		13
Net gain resulting from foreign exchange transactions		(32)
Change in assets and liabilities:
Trade accounts receivable	(285)	(23)
Other current assets and prepaid expenses	(86)	(258)
Write off of patents	76
Other assets	275	(586)
Accounts payable and accrued expenses	533	(35)
Other current liabilities	3	(10)
Due to Related Party	654	2
Due from Related Party	(280)
Accrued Interest - Related Party	649
Other liabilities	104	118
Net cash used in operating activities	(3,132)	(1,815)
Investing activities
Purchases of property and equipment	(399)	(710)
Proceeds from sale and maturity of marketable securities	25,031	6,670
Purchase of investments		(151)
Cash advances to IDT Corporation, net of repayments		(1,700)
Investment in Rafael Pharmaceuticals	(55,870)
Net cash (used in) provided by investing activities	(31,238)	4,109
Financing activities
Contribution from noncontrolling interest of consolidated entity	4,587
Repayment of loan by Rafael Pharmaceuticals, including interest	3,335
Proceeds from sale of shares	7,777
Proceeds from exercise of options	190	864
Cash advances from IDT Corporation, net of repayments		886
Proceeds from issuance of convertible note	15,000
Net cash provided by financing activities	30,889	1,750
Effect of exchange rate changes on cash and cash equivalents	(298)	3
Net (decrease) increase in cash and cash equivalents	(3,779)	4,047
Cash and cash equivalents at beginning of year	15,803	11,756
Cash and cash equivalents at end of year	12,024	15,803
Supplemental Schedule of Non-Cash Investing and Financing Activities
Adoption effect of ASU 2016-01	39
Beneficial conversion feature of convertible debt – related party	71
Series D Convertible Note and accrued interest converted to Series D Preferred Stock	10,848
Related Party deposit utilized to purchase Class B Common Stock	864
Cash payments made for taxes
Cash payments made for interest

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Rafael Holdings, Inc. ("Rafael Holdings" or the "Company"), a Delaware corporation, owns interests in commercial real estate assets and clinical-stage pharmaceutical companies. The assets are operated as two separate lines of business. The commercial real estate holdings consist of the building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company, certain affiliated entities, and an associated 800-car public garage, an office/data center building in Piscataway, New Jersey and a portion of a building in Israel. The pharmaceutical holdings include preferred equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical-stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical-stage oncological pharmaceutical company based in Israel. On March 26, 2018, IDT Corporation, or IDT, the former parent corporation of the Company, completed a tax-free spinoff (the "Spin-Off") of the Company's capital stock, through a pro rata distribution of common stock to its stockholders of record as of the close of business on March 13, 2018. Basis of Presentation The "Company" in these financial statements refers to Rafael Holdings on a consolidated basis from the date of the Spin-Off and on a combined basis from the date prior to the Spin-Off as if Rafael Holdings existed and owned the above interests in all periods presented. The Company's fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal year 2019 refers to the fiscal year ended July 31, 2019). The preparation of our consolidated and combined financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All majority-owned subsidiaries are consolidated and combined with all intercompany transactions and balances being eliminated in consolidation or combination. The entities included in these financial statements are as follows: Company Country of Incorporation Percentage Rafael Holdings, Inc. Unites States – Delaware 100 % Broad Atlantic Associates, LLC Unites States – Delaware 100 % IDT 225 Old NB Road, LLC Unites States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % IDT Capital, Inc. Unites States – Delaware 100 % IDT-Rafael Holdings, LLC Unites States – Delaware 90 % CS Pharma Holdings, LLC Unites States – Delaware 45 %* LipoMedix Pharmaceuticals Ltd. Israel 50.6 % * 50% of CS Pharma Holdings, LLC is owned by IDT-Rafael Holdings, LLC. We have a 90% ownership in IDT-Rafael Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Reclassifications Certain line items in prior period financial statements have been reclassified to conform to currently reported presentations. The Company's Spin-Off The Company was formerly a subsidiary of IDT. On March 26, 2018, IDT spun-off the Company to IDT's stockholders and the Company became an independent public company through a pro rata distribution of the Company's common stock held by IDT to IDT's stockholders. As a result of the Spin-Off, each of IDT's stockholders received: (i) one share of the Company's Class A common stock for every two shares of IDT's Class A common stock held of record on March 13, 2018 (the "Record Date"), and (ii) one share of the Company's Class B common stock for every two shares of IDT's Class B common stock held of record on the Record Date. On March 26, 2018, 787,163 shares of the Company's Class A common stock and 11,754,835 shares of the Company's Class B common stock were issued and outstanding, which includes 114,945 restricted stock units issued to employees and consultants in connection with the Spin-Off. The Company entered into various agreements with IDT prior to the Spin-Off including a Separation and Distribution Agreement to effect the separation and provide a framework for the Company's relationship with IDT after the Spin-Off, and a Transition Services Agreement, which provides for certain services to be performed by IDT to facilitate the Company's transition into a separate publicly-traded company. These agreements provide for, among other things, (1) the allocation between the Company and IDT of employee benefits, taxes and other liabilities and obligations attributable to periods prior to the Spin-Off, (2) transitional services to be provided by IDT relating to human resources and employee benefits administration, and (3) finance, accounting, tax, investor relations and legal services to be provided by IDT to the Company following the Spin-Off. In addition, the Company entered into a Tax Separation Agreement with IDT, which sets forth the responsibilities of the Company and IDT with respect to, among other things, liabilities for federal, state, local and foreign taxes for periods before and including the Spin-Off, the preparation and filing of tax returns for such periods and disputes with taxing authorities regarding taxes for such periods. Cash and Cash Equivalents The Company considers all liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Concentration of Credit Risk and Significant Customers The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the year ended July 31, 2019, related parties and one other customer represented 53%, and 10% of the Company's revenue, respectively, and as of July 31, 2019, five customers represented 38%, 17%, 16%, 12%, and 7% of the Company's accounts receivable balance, respectively. For the year ended July 31, 2018, related parties and one other customer represented 51%, and 10% of the Company's revenue, respectively, and as of July 31, 2018, five customers represented 28%, 16%, 12%, 12%, and 12% of the Company's accounts receivable balance, respectively. Allowance for Doubtful Accounts The allowance for doubtful accounts reflects the Company's best estimate of probable losses inherent in the accounts receivable balance. The allowance is determined based on known troubled accounts, historical experience and other currently available evidence. Doubtful accounts are written-off upon final determination that the trade accounts will not be collected. The computation of this allowance is based on the tenants' or parking customers' payment histories and current credit statuses, as well as certain industry or geographic specific credit considerations. If the Company's estimates of collectability differ from the cash received, then the timing and amount of the Company's reported revenue could be impacted. The credit risk is mitigated by the high quality of the Company's existing tenant base, inclusive of related parties, which represented 53% and 51% of the Company's total revenue for the years ended July 31, 2019 and 2018, respectively. The Company recorded bad debt expense of approximately $40,000 and $0 for the years ended July 31, 2019 and 2018, respectively. Investments The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated and combined financial statements include the Company's controlled affiliates. In addition, Rafael Pharmaceuticals (see Note 2) is a variable interest entity; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals' economic performance. All significant intercompany accounts and transactions between the consolidated and combined affiliates are eliminated. Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. Cost method investments are presented as "Investments - Rafael Pharmaceuticals" and "Investments – Other Pharmaceuticals" in the accompanying consolidated balance sheets. The Company no longer has investments accounted for under the equity method since the consolidation of LipoMedix in November 2017. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in "Other Expenses, net" in the accompanying consolidated and combined statements of operations, and a new basis in the investment is established. Long-Lived Assets Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, which range as follows: Classification Years Building and improvements 40 Tenant improvements 7-15 Other (primarily equipment and furniture and fixtures) 5 The Company tests the recoverability of its long-lived assets with finite useful lives whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company tests for recoverability based on the projected undiscounted cash flows to be derived from such asset. If the projected undiscounted future cash flows are less than the carrying value of the asset, the Company will record an impairment loss, if any, based on the difference between the estimated fair value and the carrying value of the asset. The Company generally measures fair value by considering sale prices for similar assets or by discounting estimated future cash flows from such asset using an appropriate discount rate. Cash flow projections and fair value estimates require significant estimates and assumptions by management. Should the estimates and assumptions prove to be incorrect, the Company may be required to record impairments in future periods and such impairments could be material. Properties The Company owns commercial real estate located at 520 Broad Street, Newark, New Jersey, and a related 800-car public parking garage across the street, as well as a building located at 225 Old New Brunswick Road in Piscataway, New Jersey. Additionally, the Company owns a portion of the 6 th Revenue Recognition In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) The Company disaggregates its revenue by source within its consolidated and combined statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing space to tenants at its properties. As a result, the majority of the Company's revenue is accounted for pursuant to ASC 840 Leases Leases Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. In addition, the Company has certain lease arrangements for parking accounted for under the guidance in ASC 840. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company's performance obligation is satisfied, consistent with the Company's previous accounting. Income Taxes The accompanying consolidated and combined financial statements include provisions for federal, state and foreign income taxes. Prior to the Spin-Off, the Company joined with its Parent and other affiliates in filing a federal income tax return on a combined basis. Income taxes for the Company for periods prior to the Spin-Off are calculated on a separate tax return basis. Our income taxes for the period subsequent to the Spin-Off will be filed on our initial consolidated standalone return with the IRS. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of such change. The Company uses a two-step approach for recognizing and measuring tax benefits taken or expected to be taken in a tax return. The Company determines whether it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, the Company presumes that the position will be examined by the appropriate taxing authority that has full knowledge of all relevant information. Tax positions that meet the more-likely-than-not recognition threshold are measured to determine the amount of tax benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Differences between tax positions taken in a tax return and amounts recognized in the financial statements will generally result in one or more of the following: an increase in a liability for income taxes payable, a reduction of an income tax refund receivable, a reduction in a deferred tax asset, or an increase in a deferred tax liability. The Company classifies interest and penalties on income taxes as a component of income tax expense, if any. Contingencies The Company accrues for loss contingencies when both (a) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (b) the amount of loss can reasonably be estimated. When the Company accrues for loss contingencies and the reasonable estimate of the loss is within a range, the Company records its best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company discloses an estimated possible loss or a range of loss when it is at least reasonably possible that a loss may have been incurred. Fair Value Measurements Fair value of financial and non-financial assets and liabilities is defined as an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three-tier hierarchy for inputs used to measure fair value, which prioritizes the inputs to valuation techniques used to measure fair value, is as follows: Level 1 quoted prices in active markets for identical assets or liabilities; Level 2 quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or Level 3 unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. A financial asset's or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. Functional Currency The U.S. Dollar is the functional currency of our entities operating in the United States. The functional currency for our subsidiary operating outside of the United States is the New Israeli Shekel, the currency of the primary economic environment in which the subsidiary primarily expends cash. The Company translates that subsidiary's financial statements into U.S. Dollars. The Company translates assets and liabilities at the exchange rate in effect as of the financial statement date, and translate accounts from the statements of comprehensive loss using the weighted average exchange rate for the period. The Company reports gains and losses from currency exchange rate changes related to intercompany receivables and payables, currently in non-operating expenses. Research and Development Costs Costs for research and development are charged to expense as incurred. Research and development costs in the relevant periods were incurred solely by LipoMedix. Repairs and Maintenance The Company charges the cost of repairs and maintenance, including the cost of replacing minor items not constituting substantial betterment, to selling, general and administrative expenses as these costs are incurred. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted earnings (loss) per share is determined in the same manner as basic earnings (loss) per share, except that the number of shares is increased to include restricted stock still subject to risk of forfeiture and to assume exercise of potentially dilutive stock options using the treasury stock method, unless the effect of such increase would be anti-dilutive. Stock-Based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Accounting for Stock Compensation Recently Issued Accounting Standards Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, Recently Adopted Accounting Pronouncements In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Accumulated Other Comprehensive Income Accumulated Deficit (in thousands) Balances as of July 31, 2018 $ 4,043 $ (1,108 ) Impact from adoption of ASU 2016-01 39 ( 39 ) Balances as of August 1, 2018 $ 4,082 $ (1,147 ) SEC Disclosure Update and Simplification In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company included a reconciliation of the changes in equity in its Form 10-Q for the quarter ended April 30, 2019.

Investment in Rafael Pharmaceut

Investment in Rafael Pharmaceuticals	12 Months Ended
	Jul. 31, 2019
Schedule of Investments [Abstract]
INVESTMENT IN RAFAEL PHARMACEUTICALS	NOTE 2 – INVESTMENT IN RAFAEL PHARMACEUTICALS Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The Company owns interests/rights in Rafael Pharmaceutical through a 90%-owned non-operating subsidiary, IDT-Rafael Holdings, LLC, or IDT-Rafael Holdings. IDT-Rafael Holdings also owns 50% of CS Pharma Holdings, LLC ("CS Pharma"), a non-operating entity. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma. Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals owns 10% of IDT-Rafael Holdings. IDT-Rafael Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the "Warrant"). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments, and will expire upon the earlier of December 31, 2020, a qualified initial public offering, or liquidation event of Rafael Pharmaceuticals. IDT-Rafael Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors. CS Pharma holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Rafael Pharmaceuticals which was converted in January 2019. The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 38% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distribute first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. The Company serves as the managing member of IDT-Rafael Holdings, and IDT-Rafael Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle IDT-Rafael Holdings to 50% (based on current ownership) of such distributions. Similarly, if IDT-Rafael Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions. The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323, Investments - Equity Method and Joint Ventures Rafael Pharmaceuticals is a variable interest entity; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals' economic performance. In addition, the interests held in Rafael Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock. Separately, Howard Jonas and Deborah Jonas jointly own $525,000 of Series C Convertible Notes of Rafael Pharmaceuticals, and The Howard S. and Deborah Jonas Foundation owns $525,000 of Series C Notes of Rafael Pharmaceuticals. On September 19, 2017, IDT approved a compensatory arrangement with Howard Jonas related to the right held by IDT-Rafael Holdings to receive additional Rafael Pharmaceutical shares ("Bonus Shares") upon the achievement of certain milestones. Under that arrangement, IDT and the Company transferred to Howard Jonas the contractual right to receive "Bonus Shares" for an additional 10% of the fully diluted capital stock of Rafael Pharmaceuticals at the time of issuance that was previously held by IDT-Rafael Holdings, which is contingent upon achieving certain milestones. This right was previously held by IDT-Rafael Holdings, subject to its right to transfer to recipients that IDT-Rafael Holdings, in its sole discretion, felt merit because of special efforts by such persons in assisting Rafael Pharmaceuticals and its products. IDT-Rafael Holdings distributed the rights to its members and the Company transferred the portion it received to Howard Jonas. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Howard Jonas has the right to transfer the Bonus Shares, in his discretion, to others, including those who are instrumental to the future success of Rafael Pharmaceuticals. Based on the current shares issued and outstanding of Rafael Pharmaceuticals as of October 2, 2019, we and our affiliates would need to pay approximately $15 million to exercise the Warrant in full. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), we and our affiliates would need to pay approximately $45 million to exercise the Warrant to keep our ownership at 51%. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), we and our affiliates would need to pay approximately $70 million to exercise the Warrant in full. Howard Jonas holds 10% of the interest in IDT Rafael Holdings and would need to contribute 10% of any cash needed to exercise any portion of the Warrant. Following any exercise, a portion of our interest in Rafael Pharmaceuticals would continue to be held for the benefit of the other equity holders in IDT-Rafael Holdings and CS Pharma. If the Bonus Shares are issued to Howard Jonas or Rafael Pharmaceuticals issues any additional equity instruments, we will need additional cash to maintain our ownership percentage or exercise the Warrant in full.

Marketable Securities

Marketable Securities	12 Months Ended
	Jul. 31, 2019
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 3 – MARKETABLE SECURITIES During fiscal 2019, all marketable securities held by the Company were liquidated in connection with the partial exercise of the Rafael Pharmaceuticals Warrant. There were no marketable securities held by the Company as of July 31, 2019. The following is a summary of marketable securities as of July 31, 2018: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Available-for-sale securities: July 31, 2018: Certificates of deposit* $ 7,757 $ — $ (23 ) $ 7,734 Federal Government Sponsored Enterprise notes 2,837 — (23 ) 2,814 International agency notes 522 — (17 ) 505 Mutual funds 5,469 — (98 ) 5,371 Corporate bonds 2,948 1 (56 ) 2,893 U.S. Treasury notes 5,476 — (92 ) 5,384 Municipal bonds — — — — Total $ 25,009 $ 1 $ (309 ) $ 24,701 * Each of the Company's certificates of deposit has a CUSIP, was purchased in the secondary market through a broker, and may be sold in the secondary market. Proceeds from maturities and sales of available-for-sale securities were $25.0 million and $6.7 million in fiscal years 2019 and 2018, respectively. The gross realized gains that were included in earnings as a result of sales were $330,000 and $12,000 in fiscal years 2019 and 2018, respectively. There were no gross realized losses that were included in earnings as a result of sales in fiscal year 2019 or fiscal year 2018. The Company uses the specific identification method in computing the gross realized gains and gross realized losses on the sales of marketable securities.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jul. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4 – FAIR VALUE MEASUREMENTS The Fair Value Measurements and Disclosures topic of the FASB ASC requires disclosures about how fair value is determined for assets and liabilities and a hierarchy for which these assets and liabilities must be grouped is established, based on significant levels of inputs as follows: Level 1 Level 2 Level 3 The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a listing of the Company's assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of July 31, 2019 and July 31, 2018: At July 31, 2019 Level 1 Level 2 Level 3 Total Available-for-sale securities: (in thousands) Hedge Funds $ — $ — $ 5,125 $ 5,125 Total $ — $ — $ 5,125 $ 5,125 At July 31, 2018 Level 1 Level 2 Level 3 Total Available-for-sale securities: (in thousands) Marketable Securities $ 10,755 $ 13,946 $ — $ 24,701 Hedge Funds — — 4,218 4,218 Rafael Pharmaceuticals convertible promissory notes — — 7,900 7,900 Total $ 10,755 $ 13,946 $ 12,118 $ 36,819 At July 31, 2019 and July 31, 2018, the Company did not have any liabilities measured at fair value on a recurring basis. At July 31, 2018, the fair value of the Rafael Pharmaceuticals Series D Convertible Note (the "Series D Note") was classified as Level 3, was estimated based on a valuation of Rafael Pharmaceuticals by reference to recent transactions in its securities, the Series D Note investment, as well as utilizing a discounted cash flow technique under the Income Approach and other factors that could not be corroborated by the market. The Series D Note was converted into shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals in January 2019. The following table summarizes the change in the balance of the Company's assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3): At July 31, 2019 2018 (in thousands) Balance, beginning of year $ 12,118 $ 6,300 Contributions by former Parent at Spin-Off — 3,949 Conversion of Rafael Pharmaceuticals Series D Convertible Note (7,900 ) — Total gains included in earnings 907 1,869 Balance, end of year $ 5,125 $ 12,118 Prior to the Spin-Off, IDT contributed $2.0 million in investments in securities in another entity that are not liquid, which were included in "Investments - Other Pharmaceuticals" in the accompanying consolidated balance sheets. The Company's related investment is accounted for using the cost method and, therefore, this investment is not measured at fair value. Fair Value of Other Financial Instruments The estimated fair value of the Company's other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. Cash and cash equivalents, prepaid expense and other current assets, and other current liabilities. Other assets and other liabilities. The Company's financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amount of trade accounts receivable, trade accounts payable and due from related parties approximate their fair value due to their short-term nature. Other than noted above, the Company did not have any other assets or liabilities that were measured at fair value on a recurring basis as of July 31, 2019 or July 31, 2018.

Trade Accounts Receivable

Trade Accounts Receivable	12 Months Ended
	Jul. 31, 2019
Receivables [Abstract]
TRADE ACCOUNTS RECEIVABLE	NOTE 5 – TRADE ACCOUNTS RECEIVABLE Trade Accounts Receivable consisted of the following: July 31, 2019 2018 (in thousands) Trade Accounts Receivable – Third Party $ 561 $ 358 Trade Accounts Receivable – Related Party 11 11 Less Allowance for Doubtful Accounts (122 ) (82 ) Trade Accounts Receivable, net $ 450 $ 287 The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was approximately $34,000 and $88,000 as of July 31, 2019 and July 31, 2018, respectively. The noncurrent portion of deferred rental income included in Other Assets was approximately $1.4 million and $1.0 million as of July 31, 2019 and July 31, 2018, res pectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Jul. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMEN T Property and equipment consisted of the following: At July 31, 2019 2018 (in thousands) Building and Improvements $ 54,241 $ 52,818 Land 10,412 10,412 Furniture and Fixtures 1,145 1,145 Other 255 255 Construction in Progress — 1,024 66,053 65,654 Less Accumulated Depreciation (17,320 ) (15,541 ) Total $ 48,733 $ 50,113 Other property and equipment consists of other equipment and miscellaneous computer hardware. Depreciation and amortization expense pertaining to property and equipment was approximately $1.8 million and $1.7 million for fiscal years 2019 and 2018, respectively.

Investment In LipoMedix Pharmac

Investment In LipoMedix Pharmaceuticals Ltd.	12 Months Ended
	Jul. 31, 2019
Business Combinations [Abstract]
INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD.	NOTE 7 – INVESTMENT IN LIPOMEDIX PHARMACEUTICALS LTD. LipoMedix is a clinical-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. As a result of its initial $100,000 investment, the Company received approximately 3.2% of the common shares outstanding. During the second quarter of fiscal year 2017, the Company made an additional $300,000 investment in LipoMedix, increasing its ownership to 13.95% of the issued and outstanding ordinary shares, and provided LipoMedix with an additional advance of $200,000 against anticipated future equity investments. During the fourth quarter of fiscal year 2017, the Company made an additional $1.1 million investment, inclusive of the $200,000 advance, in LipoMedix, increasing its ownership to 38.86% of the issued and outstanding ordinary shares. As such, the Company began accounting for this investment under the equity method as of and for the fourth quarter of fiscal year 2017. On November 16, 2017, the Company exercised its option to purchase additional shares in LipoMedix for $900,000, which increased its ownership to 50.6% of the issued and outstanding ordinary shares. As such, the Company began consolidating this investment as of and for the second quarter of fiscal year 2018. The impact of the acquisition's purchase price allocations on the Company's consolidated balance sheet and the acquisition date fair value of the total consideration transferred were as follows: (in thousands) At Other current assets $ 16 Property and equipment, net 8 In Process Research and Development 1,575 Patents 155 Accounts payable (85 ) Accrued expenses (22 ) Net assets, excluding cash acquired and noncontrolling interest $ 1,647 Supplemental information: Cash paid $ 2,400 Cash acquired 1,060 Cash paid, net of cash acquired 1,340 Historical loss on investment (252 ) Noncontrolling interest 559 Total consideration, net of cash acquired and noncontrolling interest $ 1,647 The noncontrolling interest balance of LipoMedix of approximately $559,000 was not included in the balance of noncontrolling interest as of July 31, 2018. An opening balance adjustment was booked as of August 1, 2018 to correct this amount. In 2019, the Company changed its accounting for recording patent fees. All fees associated with the legal costs incurred in connection with a patent application are being expensed as incurred including all prior legal costs for the patent costs previously capitalized. These expenses, totaling approximately $440,000 are included in selling, general, and administrative expense in the accompanying consolidated and combined financial statements. In April 2019, the Company provided no-interest bridge financing of $250,000 to LipoMedix (the "2019 Bridge Note"). The 2019 Bridge Note is automatically convertible into shares of LipoMedix as follows: (i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the Bridge Notes); or (ii) upon a liquidation or dissolution of LipoMedix or a sale of LipoMedix or its assets. If converted, the 2019 Bridge Note will be converted into shares of the most senior class of equity of LipoMedix then issued. If converted upon an equity financing, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the price paid in the equity offering. If converted upon a liquidation or sale event, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the event or if greater the Company will receive a payment equal to the 2019 Bridge Note ($250,000). If none of such events occurs prior to September 28, 2019, the 2019 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million). In July 2018, the Company provided no-interest bridge financing of $875,000 to LipoMedix (the "2018 Bridge Note"). The 2018 Bridge Note is convertible into shares of LipoMedix as follows: (i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the 2018 Bridge Note) (the "Financing"), the 2018 Bridge Note amount shall be converted into shares of LipoMedix of the same class and series with the same rights, preferences and privileges as shall be issued in the Financing at a conversion price per share equal to 75% or the lowest price per share paid by the investor(s) in the Financing; (ii) upon a Distribution Event (as defined in the Founder's Agreement among LipoMedix and certain of its founders), the 2018 Bridge Note shall be converted into shares of the most senior class of shares of LipoMedix then issued, at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the Distribution Event, or the Company shall be entitled to receive a redemption payment equal to the 2018 Bridge Note ($875,000); and (iii) if neither a Financing nor Distribution Event occurs prior to January 6, 2020 (18 months following the effective date of the 2018 Bridge Note), the 2018 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million, divided by its fully diluted share capital as of July 6, 2018).

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES On December 22, 2017, the U.S. government enacted "An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for fiscal Year 2018", which is commonly referred to as "The Tax Cuts and Jobs Act" (the "Tax Act"). The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred ("transition tax"), and creates new taxes on certain foreign sourced earnings. The Company has completed its accounting for the income tax effects of the enactment of the Tax Act. At July 31, 2019, the Company did not have any undistributed earnings of its foreign subsidiaries. As a result, no additional income or withholding taxes were provided for, for the undistributed earnings or any additional outside basis differences inherent in the foreign entities. The Company reviewed the global intangible low taxed income ("GILTI") and base erosion anti-abuse tax ("BEAT") that became effective August 1, 2018 and has not recorded any impact associated with either. At July 31, 2019, the Company has federal net operating loss ("NOL") carryforwards from domestic operations of approximately $22.3 million, to offset future taxable income. The Company has state NOLs of $3.2 million. The Company has NOLs from foreign operations of $1.2 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire. The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the SEC, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company's provisional estimates when the accounting for the income tax effects of the Tax Act is completed. The components of loss before income taxes are as follows: For the Year Ended 2019 2018 (in thousands) Domestic $ (3,410 ) $ (2,581 ) Foreign (1,533 ) (1,058 ) Loss before Income Taxes $ (4,943 ) $ (3,639 ) Benefits from (provision for) income taxes as presented in the consolidated and combined statement of operations consisted of the following: For the Year Ended 2019 2018 (in thousands) Current: Foreign $ — $ 11 Federal — — State — — Total current expense — 11 Deferred: Foreign (19 ) — Federal — 8,219 State — 207 Total deferred expense (19 ) 8,426 Income tax (benefit) expense $ (19 ) $ 8,437 The differences between income taxes expected at the U.S. federal statutory income tax rate and income taxes are reported as follows: At July 31, 2019 2018 (in thousands) U.S. federal income tax at statutory rate $ (908 ) $ (886 ) State income tax (172 ) (141 ) Valuation allowance (30 ) 7,105 Foreign tax rate differential (24 ) (290 ) Tax law change — 2,499 Permanent differences 102 144 Rate Change 1,030 — Other (17 ) 6 Income tax expense $ (19 ) $ 8,437 The Company has not recorded U.S. income tax expense for foreign earnings because it has not recorded any post spin off from IDT. Significant components of the Company's deferred tax assets and deferred tax liabilities are as follows: At July 31, 2019 2018 (in thousands) Deferred tax assets: Net operating loss carryforwards $ 5,316 $ 5,753 AMT carryforwards 2,692 — Reserves and accruals 34 2,344 Stock-based compensation 119 14 Gross deferred tax assets 8,161 8,111 Less valuation allowance (8,142 ) (8,111 ) Total deferred tax assets 19 — Total deferred tax liabilities — — Deferred tax assets, net $ 19 $ — Net deferred tax assets are included in "Deferred Taxes" in the consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Legal Proceedings On August 21, 2018, the Company entered into a settlement agreement with a building service provider in order to avoid the risks, delays and expenses inherent in and resulting from litigation. The $100,000 settlement was included in "Selling, general and administrative" expenses in the 2018 consolidated and combined statements of operations and in "Accrued Expenses" in the accompanying consolidated balance sheets. As the Company is fully indemnified by IDT for the settlement amount, a corresponding receivable was included in "Due to Related Parties" in the accompanying consolidated balance sheets. This amount has since been repaid in the first quarter of fiscal 2019. Under a Founders Agreement among LipoMedix and other parties, two of LipoMedix' founders would become entitled to consulting payments in the approximate amounts of $385,000 and $358,000, respectively, upon the satisfaction of certain conditions thereto. LipoMedix believes that those conditions have not been satisfied and does not believe that they are likely to be satisfied until LipoMedix is successful in raising significant capital in the future. On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix' bank accounts and other assets to protect his claim. LipoMedix did not believe that the individual had the right to receive any payment at the current time. LipoMedix responded to the demand for the placement of restrictions on its assets. And on November 26, 2018, the court denied the request by the founder to place restrictions on the assets. In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees. On July 15, 2019, the parties settled the matters and the two founders will be paid a percentage of future investments and certain other proceeds On July 12, 2019, the Company received a Citation and Notification of Penalty from the Occupational Safety and Health Administration of the U.S. Department of Labor or OSHA, related to an OSHA inspection of 520 Broad Street, Newark, NJ. The citation seeks to impose penalties related to alleged violations of the Occupation Safety and Health Act of 1970 at 520 Broad Street. On July 31, 2019, the Company filed a Notice of Contest with OSHA contesting the citation in its entirety. For the matters disclosed above a general legal accrual for approximately $250,000 has been made for legal fees and losses believed to be both probable and reasonably estimable, but an exposure to loss may exist in excess of the amount accrued. The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company's results of operations, cash flows or financial condition.

Convertible Note

Convertible Note	12 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTE	NOTE 10 – CONVERTIBLE NOTE On November 15, 2018, Howard Jonas, the Company's Chairman, CEO, and controlling stockholder entered into an agreement to purchase a convertible note from the Company for $15.0 million. The term of the note was three years with interest accruing on the principal amount at a rate of 6% per annum, compounded quarterly. The note was subsequently assigned by Mr. Jonas to the Howard S. Jonas 2017 Annuity Trust. At the option of the Company, interest on the note can be capitalized and added to principal or payable in cash. The note was convertible at the option of the holder into shares of Class B common stock at a conversion price of $8.47 per share, the closing price of the Company's Class B common stock on the trading day before the date of the investment agreement. The initial principal amount of the note was convertible into 1,770,956 shares of Class B common stock, and if all interest for the three-year term of the note is capitalized, the note would have been convertible into 2,117,388 shares of Class B common stock. If the closing price of the Company's Class B common stock on the NYSE American is 200% of the conversion price for at least thirty (30) consecutive days, the Company had the right to cause conversion of the note. At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $16,000 of the discount in fiscal 2019 which was included in interest expense. In addition, the Company recorded approximately $650,000 and $418,000 of interest expense for the year ended July 31, 2019 and 2018, respectively, that is included in accrued expenses in the accompanying consolidated balance sheets. At July 31, Convertible Note: (in thousands) Principal value of 6% convertible note at July 31, 2019, due November 15, 2021 $ 15,000 Debt discount (54 ) Total long-term carrying value of convertible note $ 14,946 In August 2019, the note including interest of approximately $667,000 was converted into 1,849,749 shares of common stock.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jul. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 11 – RELATED PARTY TRANSACTIONS The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Company's personnel that were paid by IDT. This is partially offset by rental income paid to the Company by various companies under common control to IDT. The Company also maintains a due from related parties account which includes the balance due for charges and for services provided by the Company to Rafael Pharmaceuticals for rent, accounting and other administrative expenses. On March 26, 2018, IDT spun off the Company. In connection with the spin-off, IDT and the Company entered into a Transition Services Agreement, dated March 26, 2018 (the "TSA"), pursuant to which IDT, which is controlled by Howard S. Jonas and for which Howard S. Jonas serves as the Chairman of the Board, provides certain services to the Company. The services include, but are not limited to: administrative, tax and legal. IDT billed the Company approximately $390,000 under the TSA during fiscal 2019 and approximately $60,000 for invoices paid by IDT on the Company's behalf. In addition, during fiscal 2019, the Company billed IDT approximately $64,000 for real estate advisory services provided to IDT, and approximately $25,000 for invoices paid by the Company on IDT's behalf. IDT collected cash of approximately $174,000 on behalf of the Company, primarily from third parties who use the Company's parking garage while the Company was in the process of changing its billing and collection systems. As of July 31, 2019, the Company owed IDT approximately $60,000 included in due to related parties. IDT leases approximately 80,000 square feet of office space plus parking occupied by IDT at 520 Broad Street, Newark, NJ and approximately 3,600 square feet of office space in Jerusalem, Israel. IDT paid the Company approximately $1.8 million for office rent and parking during fiscal 2019. As of July 31, 2019, IDT owed the Company approximately $9,000 for office rent and parking. Genie Energy, Ltd. ("Genie"), a company controlled by Howard Jonas, the Company's Chairman of the Board and controlling stockholder, leases office space from the Company at 520 Broad Street. Billings for such services totaled approximately $218,000 in fiscal 2019. The Company charges Genie $23.46 per square foot annually for approximately 8,631 square feet of space. As of July 31, 2019, Genie had no amounts due to the Company. The Company provides Rafael Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas serves as a Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. The Company billed Rafael Pharmaceuticals $480,000 during fiscal 2019. As of July 31, 2019, Rafael Pharmaceuticals owed the Company $280,000 included in due from related parties. On April 26, 2018, the Corporate Governance Committee authorized, approved and confirmed an underlying Related Person Transaction involving Howard Jonas with respect to the Company's proposed sale to Mr. Jonas of 1,254,200 shares of the Company's Class B common stock at a price per share of $6.89, which was the closing price for the Class B common stock on the NYSE American on April 26, 2018 (the last closing price before approval of the arrangement) for an aggregate purchase price of approximately $8,641,000, the purchase price of which would be reduced by the amount of any dividends whose record date is between the date hereof and the issuance of the shares (the "Sale"). The Sale took place on January 18, 2019, following stockholder approval on January 10, 2019. The Company's liability at July 31, 2018 was comprised of a deposit of $864,000 from Howard Jonas, Chairman of the Board, Chief Executive Officer and controlling stockholder of the Company partially offset by amounts due from IDT and Rafael Pharmaceuticals. IDT-Rafael Holdings, LLC, the Company's 90%-owned subsidiary and the remaining 10% of which is held by Howard Jonas, currently holds 36.7 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals. IDT-Rafael Holdings, LLC also owns 50% of CS Pharma Holdings, LLC ("CS Pharma"), a non-operating entity that holds 16.7 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock. The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 38% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). In September 2018, CS Pharma, in which the Company owns an effective 45% interest, exercised a warrant to purchase 8 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock for $10 million representing approximately 8% of the equity on a fully-diluted basis (excluding the remainder of the Warrant) of Rafael Pharmaceuticals. The Warrant in full is exercisable for up to 56% of the fully diluted equity of Rafael Pharmaceuticals. The right to exercise the first $10 million of the Warrant was held by CS Pharma. CS Pharma is owned by 0.25% by Michael Weiss, a non-employee director of the Company. The remainder of the Warrant is held by IDT-Rafael Holdings, LLC. On November 5, 2018, IDT-Rafael Holdings, LLC partially exercised a warrant to purchase 4 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock for $5 million, of which $500,000 was contributed by Howard Jonas. On January 10, 2019, IDT-Rafael Holdings, LLC partially exercised a warrant to purchase 5.1 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $6.4 million, of which $640,000 was contributed by Howard Jonas. On January 23, 2019, IDT-Rafael Holdings, LLC partially exercised a warrant to purchase 36.3 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $34.4 million, of which $3.4 million was contributed by Howard Jonas. On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15 million that has since been converted to shares of common stock. See Note 10.

Future Minimum Rents

Future Minimum Rents	12 Months Ended
	Jul. 31, 2019
Future Minimum Rents [Abstract]
FUTURE MINIMUM RENTS	NOTE 12 – FUTURE MINIMUM RENTS Certain of the Company's properties are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2030. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of July 31, 2019, under non-cancelable operating leases which expire on various dates through 2028, are as follows: Year ending July 31, Related Parties Other Total (in thousands) 2020 $ 1,992 $ 1,054 $ 3,046 2021 2,041 1,136 3,177 2022 2,078 993 3,071 2023 2,117 630 2,747 2024 2,155 1,185 3,340 Thereafter 1,659 3,468 5,127 Total Minimum Future Rental Income $ 12,042 $ 8,466 $ 20,508 Related parties represented approximately 53% and 51% of the Company's total revenue for the years ended July 31, 2019 and 2018, respectively. The Company amended all of its related party leases as of August 1, 2017. The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months' notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months' notice. IDT has the right to lease an additional 50,000 square feet, in 25,000 foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

Business Segment Information

Business Segment Information	12 Months Ended
	Jul. 31, 2019
Segment Reporting [Abstract]
BUSINESS SEGMENT INFORMATION	NOTE 13 – BUSINESS SEGMENT INFORMATION The Company conducts business as two operating segments, Real Estate and Pharmaceuticals. The Company's reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company's chief operating decision makers. The Real Estate segment consists of the Company's real estate holdings, including the building at 520 Broad Street in Newark, New Jersey that houses the Company and certain affiliates and its associated public garage, an office/data center building in Piscataway, New Jersey and a portion of an office building in Israel. Beginning in the second quarter of fiscal 2018, the Pharmaceuticals segment is comprised of debt interests and a warrant to purchase equity interests in Rafael Pharmaceuticals and a majority equity interest in LipoMedix. Comparative results have been reclassified and restated as if the Pharmaceuticals segment existed for all periods presented. To date, the Pharmaceuticals segment has not generated any revenues. The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on loss from operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment. Operating results for the business segments of the Company are as follows: (in thousands) Real Estate Pharmaceuticals Total At Year Ended July 31, 2019 Revenues $ 4,931 $ — $ 4,931 Loss from operations (5,083 ) (1,613 ) (6,696 ) At Year Ended July 31, 2018 Revenues $ 4,371 $ — $ 4,371 Loss from operations (2,780 ) (1,061 ) (3,841 ) Geographic Information Revenues from tenants located outside of the United States were generated entirely from related parties located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility): Year Ended July 31, 2019 2018 Revenue from tenants located in Israel 3 % 6 % Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows: (in thousands) United States Israel Total July 31, 2019 Long-lived assets, net $ 47,096 $ 1,637 $ 48,733 Total assets 138,535 3,608 142,143 July 31, 2018 Long-lived assets, net $ 48,415 $ 1,698 $ 50,113 Total assets 113,279 3,641 116,920

Equity

Equity	12 Months Ended
	Jul. 31, 2019
Equity [Abstract]
EQUITY	NOTE 14 – EQUITY Class A Common Stock and Class B Common Stock The rights of holders of Class A common stock and Class B common stock are identical except for certain voting and conversion rights and restrictions on transferability. The holders of Class A common stock and Class B common stock receive identical dividends per share when and if declared by the Company's Board of Directors. In addition, the holders of Class A common stock and Class B common stock have identical and equal priority rights per share in liquidation. The Class A common stock and Class B common stock do not have any other contractual participation rights. The holders of Class A common stock are entitled to three votes per share and the holders of Class B common stock are entitled to one-tenth of a vote per share. Each share of Class A common stock may be converted into one share of Class B common stock, at any time, at the option of the holder. Shares of Class A common stock are subject to certain limitations on transferability that do not apply to shares of Class B common stock. Stock-Based Compensation The Rafael Holdings, Inc. 2018 Equity Incentive Plan (the "Plan") was created and adopted by the Company in March 2018. The Plan allows for the issuance of up to 1,064,048 shares which may be awarded in the form of incentive stock options or restricted shares. In connection with the Spin-Off, options to purchase 626,662 shares of Class B common stock options were issued to IDT employees and service providers related to options to purchase IDT stock held by those individuals. The options have an exercise price of $4.90 per share, which was equal to the closing price of the Company's Class B common stock on the first trading day following the consummation of the Spin-Off. The expiration date of the options is equal to the later of (i) the expiration of the IDT option held by such option holder and (ii) a date on or about the first anniversary of the Spin-Off when the Company's insiders will be free to trade in shares of the Company under the Company's insider trading policy. The options to purchase shares of the Company were issued under the Plan. Option awards to Company employees under the Plan are generally granted with an exercise price equal to the market price of the Company's stock on the date of grant. Option awards generally vest on a graded basis over five years of service and have ten-year contractual terms. No options were granted in fiscal 2019. In fiscal 2019, options to purchase 38,710 shares of Class B common stock were exercised and 819 options were cancelled. No options were exercised or cancelled during fiscal 2018. At July 31, 2019, there was no unrecognized compensation cost related to non-vested stock options. A summary of stock option activity for the Company is as follows: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2018 626,662 $ 4.90 Granted — — Exercised (38,710 ) 4.90 Cancelled / Forfeited (819 ) 4.90 OUTSTANDING AT JULY 31, 2019 587,133 $ 4.90 3.66 $ 2,877 EXERCISABLE AT JULY 31, 2019 572,934 $ 4.90 3.66 $ 2,807 Restricted Stock Units The fair value of restricted shares of the Company's Class B common stock is determined based on the closing price of the Company's Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service. As part of the Spin-Off, holders of restricted Class B common stock of IDT received, in respect of those restricted shares, one restricted share of the Company's Class B common stock for every two restricted shares of IDT that they held as of the record date for the Spin-Off. The Company issued an aggregate of 92,690 restricted shares of its Class B common stock to the holders of restricted Class B common stock of IDT. Such shares of the Company's Class B common stock are restricted under the same terms as the IDT restricted stock in respect of which they were issued. The restricted shares of the Company's Class B common stock received in the Spin-Off are subject to forfeiture on the same terms, and their restrictions will lapse at the same time, as the corresponding IDT shares. On March 28, 2018, the Company granted employees and consultants 76,445 restricted shares of Class B Common Stock, which vested or will vest as to one-third of the granted shares on each of March 28, 2019, 2020 and 2021, unless otherwise determined by the Compensation Committee of the Company's Board of Directors. The aggregate fair value of the grant was approximately $375,000, which is being charged to expense on a straight-line basis as the shares vest. During fiscal 2019, the Company granted employees and consultants 74,637 restricted shares of Class B Common Stock, which will vest over 2 to 5 years. The aggregate fair value of the grants was approximately $1.3 million, which is being charged to expense on a straight-line basis as the shares vest. One grant of 70,718 restricted shares with a fair value of $1.2 million was granted to an officer of the Company. A summary of the status of the Company's grants of restricted shares of Class B common stock is presented below: Number of Weighted- Average Outstanding at July 31, 2018 141,799 $ 4.90 Granted 74,637 16.49 Vested (60,010 ) 4.96 Cancelled / Forfeited — — NON-VESTED SHARES AT JULY 31, 2019 156,426 $ 10.41 At July 31, 2019, there was $1.2 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over a weighted-average period of three years. The total grant date fair value of shares vested in fiscal 2019 and fiscal 2018 was approximately $298,000 and $344,000, respectively. Approval of Sale of Shares of Class B Common Stock to Howard S. Jonas On April 26, 2018, the Corporate Governance Committee authorized, approved and confirmed an underlying Related Person Transaction involving Howard Jonas with respect to the Company's proposed sale to Mr. Jonas of 1,254,200 shares of the Company's Class B common stock at a price per share of $6.89, which was the closing price for the Class B common stock on the NYSE American on April 26, 2018 (the last closing price before approval of the arrangement) for an aggregate purchase price of $8,641,438, the purchase price of which would be reduced by the amount of any dividends whose record date is between the date hereof and the issuance of the shares (the "Sale"). The Sale took place on January 18, 2019, following stockholder approval on January 10, 2019. Grant to Board of Directors Pursuant to the Company's 2018 Equity Incentive Plan, each of our three non-employee directors of the Company was granted 4,203 restricted shares of our Class B common stock in January 2019 which fully vested on the date of the grant. The fair value of the awards on the date of the grant was approximately $107,000, which was included in selling, general and administrative expense.

Loss Per Share

Loss Per Share	12 Months Ended
	Jul. 31, 2019
Loss per share attributable to Rafael Holdings, Inc. common stockholders:
LOSS PER SHARE	NOTE 15 – LOSS PER SHARE Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per shares includes potentially dilutive securities such as stock options and other convertible instruments. For the years ended July 31, 2019 and 2018, these securities have been excluded from the calculation of diluted net loss per shares because all such securities are anti-dilutive for all periods presented. The following table summarizes the Company's securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: At July 31, 2019 2018 Stock Options 587,133 626,662 Convertible Note – Related Party 1,847,594 — Total 2,434,727 626,662 In the years ended July 31, 2019 and 2018, the diluted loss per share computation equals basic loss per share because the Company had a net loss and the impact of the assumed exercise of stock options and conversion of the convertible note would have been anti-dilutive.

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Description of Business	Description of Business Rafael Holdings, Inc. ("Rafael Holdings" or the "Company"), a Delaware corporation, owns interests in commercial real estate assets and clinical-stage and development-stage pharmaceutical companies. The assets are operated as two separate lines of business. The commercial real estate holdings consist of the building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company, certain affiliated entities, and an associated 800-car public garage, an office/data center building in Piscataway, New Jersey and a portion of a building in Israel. The pharmaceutical holdings include preferred equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical-stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a development-stage oncological pharmaceutical company based in Israel. On March 26, 2018, IDT Corporation, or IDT, the former parent corporation of the Company, completed a tax-free spinoff (the "Spin-Off") of the Company's capital stock, through a pro rata distribution of common stock to its stockholders of record as of the close of business on March 13, 2018.
Basis of Presentation	Basis of Presentation The "Company" in these financial statements refers to Rafael Holdings on a consolidated basis from the date of the Spin-Off and on a combined basis from the date prior to the Spin-Off as if Rafael Holdings existed and owned the above interests in all periods presented. The Company's fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal year 2019 refers to the fiscal year ended July 31, 2019). The preparation of our consolidated and combined financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All majority-owned subsidiaries are consolidated and combined with all intercompany transactions and balances being eliminated in consolidation or combination. The entities included in these financial statements are as follows: Company Country of Incorporation Percentage Rafael Holdings, Inc. Unites States – Delaware 100 % Broad Atlantic Associates, LLC Unites States – Delaware 100 % IDT 225 Old NB Road, LLC Unites States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % IDT Capital, Inc. Unites States – Delaware 100 % IDT-Rafael Holdings, LLC Unites States – Delaware 90 % CS Pharma Holdings, LLC Unites States – Delaware 45 %* LipoMedix Pharmaceuticals Ltd. Israel 50.6 % * 50% of CS Pharma Holdings, LLC is owned by IDT-Rafael Holdings, LLC. We have a 90% ownership in IDT-Rafael Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.
Reclassifications	Reclassifications Certain line items in prior period financial statements have been reclassified to conform to currently reported presentations.
The Company's Spin-Off	The Company's Spin-Off The Company was formerly a subsidiary of IDT. On March 26, 2018, IDT spun-off the Company to IDT's stockholders and the Company became an independent public company through a pro rata distribution of the Company's common stock held by IDT to IDT's stockholders. As a result of the Spin-Off, each of IDT's stockholders received: (i) one share of the Company's Class A common stock for every two shares of IDT's Class A common stock held of record on March 13, 2018 (the "Record Date"), and (ii) one share of the Company's Class B common stock for every two shares of IDT's Class B common stock held of record on the Record Date. On March 26, 2018, 787,163 shares of the Company's Class A common stock and 11,754,835 shares of the Company's Class B common stock were issued and outstanding, which includes 114,945 restricted stock units issued to employees and consultants in connection with the Spin-Off. The Company entered into various agreements with IDT prior to the Spin-Off including a Separation and Distribution Agreement to effect the separation and provide a framework for the Company's relationship with IDT after the Spin-Off, and a Transition Services Agreement, which provides for certain services to be performed by IDT to facilitate the Company's transition into a separate publicly-traded company. These agreements provide for, among other things, (1) the allocation between the Company and IDT of employee benefits, taxes and other liabilities and obligations attributable to periods prior to the Spin-Off, (2) transitional services to be provided by IDT relating to human resources and employee benefits administration, and (3) finance, accounting, tax, investor relations and legal services to be provided by IDT to the Company following the Spin-Off. In addition, the Company entered into a Tax Separation Agreement with IDT, which sets forth the responsibilities of the Company and IDT with respect to, among other things, liabilities for federal, state, local and foreign taxes for periods before and including the Spin-Off, the preparation and filing of tax returns for such periods and disputes with taxing authorities regarding taxes for such periods.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the year ended July 31, 2019, related parties and one other customer represented 53%, and 10% of the Company's revenue, respectively, and as of July 31, 2019, five customers represented 38%, 17%, 16%, 12%, and 7% of the Company's accounts receivable balance, respectively. For the year ended July 31, 2018, related parties and one other customer represented 51%, and 10% of the Company's revenue, respectively, and as of July 31, 2018, five customers represented 28%, 16%, 12%, 12%, and 12% of the Company's accounts receivable balance, respectively.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The allowance for doubtful accounts reflects the Company's best estimate of probable losses inherent in the accounts receivable balance. The allowance is determined based on known troubled accounts, historical experience and other currently available evidence. Doubtful accounts are written-off upon final determination that the trade accounts will not be collected. The computation of this allowance is based on the tenants' or parking customers' payment histories and current credit statuses, as well as certain industry or geographic specific credit considerations. If the Company's estimates of collectability differ from the cash received, then the timing and amount of the Company's reported revenue could be impacted. The credit risk is mitigated by the high quality of the Company's existing tenant base, inclusive of related parties, which represented 53% and 51% of the Company's total revenue for the years ended July 31, 2019 and 2018, respectively. The Company recorded bad debt expense of approximately $40,000 and $0 for the years ended July 31, 2019 and 2018, respectively.
Investments	Investments The method of accounting applied to long-term investments, whether consolidated, equity or cost, involves an evaluation of the significant terms of each investment that explicitly grant or suggest evidence of control or influence over the operations of the investee and also includes the identification of any variable interests in which the Company is the primary beneficiary. The consolidated and combined financial statements include the Company's controlled affiliates. In addition, Rafael Pharmaceuticals (see Note 2) is a variable interest entity; however, the Company has determined that it is not the primary beneficiary as the Company does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals' economic performance. All significant intercompany accounts and transactions between the consolidated and combined affiliates are eliminated. Investments in businesses that the Company does not control, but in which the Company has the ability to exercise significant influence over operating and financial matters, are accounted for using the equity method. Investments in which the Company does not have the ability to exercise significant influence over operating and financial matters are accounted for using the cost method. Cost method investments are presented as "Investments - Rafael Pharmaceuticals" and "Investments – Other Pharmaceuticals" in the accompanying consolidated balance sheets. The Company no longer has investments accounted for under the equity method since the consolidation of LipoMedix in November 2017. The Company periodically evaluates its investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded in "Other Expenses, net" in the accompanying consolidated and combined statements of operations, and a new basis in the investment is established.
Long-Lived Assets	Long-Lived Assets Equipment, buildings, leasehold improvements, and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, which range as follows: Classification Years Building and improvements 40 Tenant improvements 7-15 Other (primarily equipment and furniture and fixtures) 5 The Company tests the recoverability of its long-lived assets with finite useful lives whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company tests for recoverability based on the projected undiscounted cash flows to be derived from such asset. If the projected undiscounted future cash flows are less than the carrying value of the asset, the Company will record an impairment loss, if any, based on the difference between the estimated fair value and the carrying value of the asset. The Company generally measures fair value by considering sale prices for similar assets or by discounting estimated future cash flows from such asset using an appropriate discount rate. Cash flow projections and fair value estimates require significant estimates and assumptions by management. Should the estimates and assumptions prove to be incorrect, the Company may be required to record impairments in future periods and such impairments could be material.
Properties	Properties The Company owns commercial real estate located at 520 Broad Street, Newark, New Jersey, and a related 800-car public parking garage across the street, as well as a building located at 225 Old New Brunswick Road in Piscataway, New Jersey. Additionally, the Company owns a portion of the 6 th
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) The Company disaggregates its revenue by source within its consolidated and combined statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing space to tenants at its properties. As a result, the majority of the Company's revenue is accounted for pursuant to ASC 840 Leases Leases Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. In addition, the Company has certain lease arrangements for parking accounted for under the guidance in ASC 840. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company's performance obligation is satisfied, consistent with the Company's previous accounting.
Income Taxes	Income Taxes The accompanying consolidated and combined financial statements include provisions for federal, state and foreign income taxes. Prior to the Spin-Off, the Company joined with its Parent and other affiliates in filing a federal income tax return on a combined basis. Income taxes for the Company for periods prior to the Spin-Off are calculated on a separate tax return basis. Our income taxes for the period subsequent to the Spin-Off will be filed on our initial consolidated standalone return with the IRS. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of such change. The Company uses a two-step approach for recognizing and measuring tax benefits taken or expected to be taken in a tax return. The Company determines whether it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, the Company presumes that the position will be examined by the appropriate taxing authority that has full knowledge of all relevant information. Tax positions that meet the more-likely-than-not recognition threshold are measured to determine the amount of tax benefit to recognize in the financial statements. The tax position is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Differences between tax positions taken in a tax return and amounts recognized in the financial statements will generally result in one or more of the following: an increase in a liability for income taxes payable, a reduction of an income tax refund receivable, a reduction in a deferred tax asset, or an increase in a deferred tax liability. The Company classifies interest and penalties on income taxes as a component of income tax expense, if any.
Contingencies	Contingencies The Company accrues for loss contingencies when both (a) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (b) the amount of loss can reasonably be estimated. When the Company accrues for loss contingencies and the reasonable estimate of the loss is within a range, the Company records its best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range. The Company discloses an estimated possible loss or a range of loss when it is at least reasonably possible that a loss may have been incurred.
Fair Value Measurements	Fair Value Measurements Fair value of financial and non-financial assets and liabilities is defined as an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three-tier hierarchy for inputs used to measure fair value, which prioritizes the inputs to valuation techniques used to measure fair value, is as follows: Level 1 quoted prices in active markets for identical assets or liabilities; Level 2 quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability; or Level 3 unobservable inputs for the asset or liability, such as discounted cash flow models or valuations. A financial asset's or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
Functional Currency	Functional Currency The U.S. Dollar is the functional currency of our entities operating in the United States. The functional currency for our subsidiary operating outside of the United States is the New Israeli Shekel, the currency of the primary economic environment in which the subsidiary primarily expends cash. The Company translates that subsidiary's financial statements into U.S. Dollars. The Company translates assets and liabilities at the exchange rate in effect as of the financial statement date, and translate accounts from the statements of comprehensive loss using the weighted average exchange rate for the period. The Company reports gains and losses from currency exchange rate changes related to intercompany receivables and payables, currently in non-operating expenses.
Research and Development Costs	Research and Development Costs Costs for research and development are charged to expense as incurred. Research and development costs in the relevant periods were incurred solely by LipoMedix.
Repairs and Maintenance	Repairs and Maintenance The Company charges the cost of repairs and maintenance, including the cost of replacing minor items not constituting substantial betterment, to selling, general and administrative expenses as these costs are incurred.
Earnings (Loss) Per Share	Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted earnings (loss) per share is determined in the same manner as basic earnings (loss) per share, except that the number of shares is increased to include restricted stock still subject to risk of forfeiture and to assume exercise of potentially dilutive stock options using the treasury stock method, unless the effect of such increase would be anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Accounting for Stock Compensation
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Accumulated Other Comprehensive Income Accumulated Deficit (in thousands) Balances as of July 31, 2018 $ 4,043 $ (1,108 ) Impact from adoption of ASU 2016-01 (39 ) 39 Balances as of August 1, 2018 $ 4,082 $ (1,147 )
SEC Disclosure Update and Simplification	SEC Disclosure Update and Simplification In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company included a reconciliation of the changes in equity in its Form 10-Q for the quarter ended April 30, 2019.

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Schedule of entities majority-owned subsidiaries	Company Country of Incorporation Percentage Rafael Holdings, Inc. Unites States – Delaware 100 % Broad Atlantic Associates, LLC Unites States – Delaware 100 % IDT 225 Old NB Road, LLC Unites States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % IDT Capital, Inc. Unites States – Delaware 100 % IDT-Rafael Holdings, LLC Unites States – Delaware 90 % CS Pharma Holdings, LLC Unites States – Delaware 45 %* Lipomedix Pharmaceuticals Ltd. Israel 50.6 % * 50% of CS Pharma Holdings, LLC is owned by IDT-Rafael Holdings, LLC. We have a 90% ownership in IDT-Rafael Holdings, LLC, and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.
Schedule of estimated usefull lives	Classification Years Building and improvements 40 Tenant improvements 7-15 Other (primarily equipment and furniture and fixtures) 5
Schedule of accumulated other comprehensive income	Accumulated Other Comprehensive Income Accumulated Deficit (in thousands) Balances as of July 31, 2018 $ 4,043 $ (1,108 ) Impact from adoption of ASU 2016-01 (39 ) 39 Balances as of August 1, 2018 $ 4,082 $ (1,147 )

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Jul. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Schedule of marketable securities	Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Available-for-sale securities: July 31, 2018: Certificates of deposit* $ 7,757 $ — $ (23 ) $ 7,734 Federal Government Sponsored Enterprise notes 2,837 — (23 ) 2,814 International agency notes 522 — (17 ) 505 Mutual funds 5,469 — (98 ) 5,371 Corporate bonds 2,948 1 (56 ) 2,893 U.S. Treasury notes 5,476 — (92 ) 5,384 Municipal bonds — — — — Total $ 25,009 $ 1 $ (309 ) $ 24,701 * Each of the Company's certificates of deposit has a CUSIP, was purchased in the secondary market through a broker, and may be sold in the secondary market.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jul. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of balance of assets measured at fair value on a recurring basis	At July 31, 2019 Level 1 Level 2 Level 3 Total Available-for-sale securities: (in thousands) Hedge Funds $ — $ — $ 5,125 $ 5,125 Total $ — $ — $ 5,125 $ 5,125 At July 31, 2018 Level 1 Level 2 Level 3 Total Available-for-sale securities: (in thousands) Marketable Securities $ 10,755 $ 13,946 $ — $ 24,701 Hedge Funds — — 4,218 4,218 Rafael Pharmaceuticals convertible promissory notes — — 7,900 7,900 Total $ 10,755 $ 13,946 $ 12,118 $ 36,819
Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3)	At July 31, 2019 2018 (in thousands) Balance, beginning of year $ 12,118 $ 6,300 Contributions by former Parent at Spin-Off — 3,949 Conversion of Rafael Pharmaceuticals Series D Convertible Note (7,900 ) — Total gains included in earnings 907 1,869 Balance, end of year $ 5,125 $ 12,118

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	12 Months Ended
	Jul. 31, 2019
Receivables [Abstract]
Schedule of trade accounts receivable	July 31, 2019 2018 (in thousands) Trade Accounts Receivable – Third Party $ 561 $ 358 Trade Accounts Receivable – Related Party 11 11 Less Allowance for Doubtful Accounts (122 ) (82 ) Trade Accounts Receivable, net $ 450 $ 287

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jul. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	At July 31, 2019 2018 (in thousands) Building and Improvements $ 54,241 $ 52,818 Land 10,412 10,412 Furniture and Fixtures 1,145 1,145 Other 255 255 Construction in Progress — 1,024 66,053 65,654 Less Accumulated Depreciation (17,320 ) (15,541 ) Total $ 48,733 $ 50,113

Investment In LipoMedix Pharm_2

Investment In LipoMedix Pharmaceuticals Ltd. (Tables)	12 Months Ended
	Jul. 31, 2019
Business Combinations [Abstract]
Schedule of combined balance sheet and acquisition fair value	(in thousands) At Other current assets $ 16 Property and equipment, net 8 In Process Research and Development 1,575 Patents 155 Accounts payable (85 ) Accrued expenses (22 ) Net assets, excluding cash acquired and noncontrolling interest $ 1,647 Supplemental information: Cash paid $ 2,400 Cash acquired 1,060 Cash paid, net of cash acquired 1,340 Historical loss on investment (252 ) Noncontrolling interest 559 Total consideration, net of cash acquired and noncontrolling interest $ 1,647

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of income (loss) before income taxes	For the Year Ended 2019 2018 (in thousands) Domestic $ (3,410 ) $ (2,581 ) Foreign (1,533 ) (1,058 ) Loss before Income Taxes $ (4,943 ) $ (3,639 )
Schedule of provision for income taxes	For the Year Ended 2019 2018 (in thousands) Current: Foreign $ — $ 11 Federal — — State — — Total current expense — 11 Deferred: Foreign (19 ) — Federal — 8,219 State — 207 Total deferred expense (19 ) 8,426 Income tax (benefit) expense $ (19 ) $ 8,437
Schedule of differences between income taxes	At July 31, 2019 2018 (in thousands) U.S. federal income tax at statutory rate $ (908 ) $ (886 ) State income tax (172 ) (141 ) Valuation allowance (30 ) 7,105 Foreign tax rate differential (24 ) (290 ) Tax law change — 2,499 Permanent differences 102 144 Rate Change 1,030 — Other (17 ) 6 Income tax expense $ (19 ) $ 8,437
Schedule of deferred tax assets and deferred tax liabilities	At July 31, 2019 2018 (in thousands) Deferred tax assets: Net operating loss carryforwards $ 5,316 $ 5,753 AMT carryforwards 2,692 — Reserves and accruals 34 2,344 Stock-based compensation 119 14 Gross deferred tax assets 8,161 8,111 Less valuation allowance (8,142 ) (8,111 ) Total deferred tax assets 19 — Total deferred tax liabilities — — Deferred tax assets, net $ 19 $ —

Convertible Note (Tables)

Convertible Note (Tables)	12 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term carrying value of convertible note	At July 31, Convertible Note: (in thousands) Principal value of 6% convertible note at July 31, 2019, due November 15, 2021 $ 15,000 Debt discount (54 ) Total long-term carrying value of convertible note $ 14,946

Future Minimum Rents (Tables)

Future Minimum Rents (Tables)	12 Months Ended
	Jul. 31, 2019
Future Minimum Rents [Abstract]
Schedule of non-cancelable operating leases	Year ending July 31, Related Parties Other Total (in thousands) 2020 $ 1,992 $ 1,054 $ 3,046 2021 2,041 1,136 3,177 2022 2,078 993 3,071 2023 2,117 630 2,747 2024 2,155 1,185 3,340 Thereafter 1,659 3,468 5,127 Total Minimum Future Rental Income $ 12,042 $ 8,466 $ 20,508

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Jul. 31, 2019
Segment Reporting [Abstract]
Schedule of operating results for the business segments	(in thousands) Real Estate Pharmaceuticals Total At Year Ended July 31, 2019 Revenues $ 4,931 $ — $ 4,931 Loss from operations (5,083 ) (1,613 ) (6,696 ) At Year Ended July 31, 2018 Revenues $ 4,371 $ — $ 4,371 Loss from operations (2,780 ) (1,061 ) (3,841 )
Schedule of revenue from tenants by geographic areas	Year Ended July 31, 2019 2018 Revenue from tenants located in Israel 3 % 6 %
Schedule of net long-lived assets and total assets by geographic areas	(in thousands) United States Israel Total July 31, 2019 Long-lived assets, net $ 47,096 $ 1,637 $ 48,733 Total assets 138,535 3,608 142,143 July 31, 2018 Long-lived assets, net $ 48,415 $ 1,698 $ 50,113 Total assets 113,279 3,641 116,920

Equity (Tables)

Equity (Tables)	12 Months Ended
	Jul. 31, 2019
Equity [Abstract]
Schedule of stock option activity	Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2018 626,662 $ 4.90 Granted — — Exercised (38,710 ) 4.90 Cancelled / Forfeited (819 ) 4.90 OUTSTANDING AT JULY 31, 2019 587,133 $ 4.90 3.66 $ 2,877 EXERCISABLE AT JULY 31, 2019 572,934 $ 4.90 3.66 $ 2,807
Schedule of grants of restricted shares of Class B common stock	Number of Weighted- Average Outstanding at July 31, 2018 141,799 $ 4.90 Granted 74,637 16.49 Vested (60,010 ) 4.96 Cancelled / Forfeited — — NON-VESTED SHARES AT JULY 31, 2019 156,426 $ 10.41

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Jul. 31, 2019
Loss per share attributable to Rafael Holdings, Inc. common stockholders:
Schedule of common share equivalents, basic and dilutive loss per share	At July 31, 2019 2018 Stock Options 587,133 626,662 Convertible Note – Related Party 1,847,594 — Total 2,434,727 626,662

Description of Business and S_4

Description of Business and Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jul. 31, 2019
Rafael Holdings, Inc. [Member]
Country of Incorporation	Unites States – Delaware
Percentage Owned	100.00%
Broad Atlantic Associates, LLC [Member]
Country of Incorporation	Unites States – Delaware
Percentage Owned	100.00%
IDT 225 Old NB Road, LLC [Member]
Country of Incorporation	Unites States – Delaware
Percentage Owned	100.00%
IDT R.E. Holdings Ltd. [Member]
Country of Incorporation	Israel
Percentage Owned	100.00%
IDT Capital, Inc. [Member]
Country of Incorporation	Unites States – Delaware
Percentage Owned	100.00%
IDT-Rafael Holdings, LLC [Member]
Country of Incorporation	Unites States – Delaware
Percentage Owned	90.00%
CS Pharma Holdings, LLC [Member]
Country of Incorporation	Unites States – Delaware
Percentage Owned	45.00%	[1]
Lipomedix Pharmaceuticals Ltd. [Member]
Country of Incorporation	Israel
Percentage Owned	50.60%
[1]	50% of CS Pharma Holdings, LLC is owned by IDT-Rafael Holdings, LLC. We have a 90% ownership in IDT-Rafael Holdings, LLC, and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

Description of Business and S_5

Description of Business and Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Jul. 31, 2019
Building and improvements [Member]
Estimated useful lives	40 years
Tenant improvements [Member] | Maximum [Member]
Estimated useful lives	15 years
Tenant improvements [Member] | Minimum [Member]
Estimated useful lives	7 years
Other (primarily equipment and furniture and fixtures) [Member]
Estimated useful lives	5 years

Description of Business and S_6

Description of Business and Summary of Significant Accounting Policies (Details 2) $ in Thousands	12 Months Ended
	Jul. 31, 2019USD ($)
Accumulated Other Comprehensive Income [Member]
Beginning Balance	$ 4,043
Impact from adoption of ASU 2016-01	39
Ending Balance	4,082
Accumulated Deficit [Member]
Beginning Balance	(1,108)
Impact from adoption of ASU 2016-01	(39)
Ending Balance	$ (1,147)

Description of Business and S_7

Description of Business and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 26, 2018shares	Jul. 31, 2019USD ($)Customersshares	Jul. 31, 2018USD ($)Customersshares
Description of Business and Basis of Presentation (Textual)
Bad debt expense | $		$ 122
Interest Income | $		$ 333
Common Stock, Series B
Description of Business and Basis of Presentation (Textual)
Common stock, shares issued		13,142,502	11,762,346
Common stock, shares outstanding		13,142,502	11,762,346
Common Stock, Series B | Subsidiaries [Member]
Description of Business and Basis of Presentation (Textual)
Common stock, shares issued	11,754,835
Common stock, shares outstanding	11,754,835
Common Stock, Series A
Description of Business and Basis of Presentation (Textual)
Common stock, shares issued		787,163	787,163
Common stock, shares outstanding		787,163	787,163
Common Stock, Series A | Subsidiaries [Member]
Description of Business and Basis of Presentation (Textual)
Common stock, shares issued	787,163
Common stock, shares outstanding	787,163
IDT Rafael Holdings, LLC [Member]
Description of Business and Basis of Presentation (Textual)
Spin-off common stock, description		(i) one share of the Company's Class A common stock for every two shares of IDT's Class A common stock held of record on March 13, 2018 (the "Record Date"), and (ii) one share of the Company's Class B common stock for every two shares of IDT's Class B common stock held of record on the Record Date. On March 26, 2018, 787,163 shares of the Company's Class A common stock and 11,754,835 shares of the Company's Class B common stock were issued and outstanding, which includes 114,945 restricted stock units issued to employees and consultants in connection with the Spin-Off.
Accounts receivable [Member]
Description of Business and Basis of Presentation (Textual)
Bad debt expense | $		$ 40	$ 0
Revenue [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage			10.00%
Number of customers | Customers			1
Revenue [Member] | Related Party [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		0.00%	51.00%
Revenue [Member] | Related Parties [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		53.00%	51.00%
Geographic Concentration Risk [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage			6.00%
Customer One [Member] | Accounts receivable [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		38.00%	28.00%
Number of customers | Customers		5	5
Customer One [Member] | Revenue [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage			10.00%
Number of customers | Customers		1
Customer Two [Member] | Accounts receivable [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		17.00%	16.00%
Number of customers | Customers		5	5
Customer Three [Member] | Accounts receivable [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		16.00%	12.00%
Number of customers | Customers		5	5
Customer Four [Member] | Accounts receivable [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		12.00%	12.00%
Number of customers | Customers		5	5
Customer Five [Member] | Accounts receivable [Member]
Description of Business and Basis of Presentation (Textual)
Concentration risk percentage		7.00%	12.00%
Number of customers | Customers		5	5
Employee Stock [Member]
Description of Business and Basis of Presentation (Textual)
Restricted stock units issued	114,945
Consultants [Member]
Description of Business and Basis of Presentation (Textual)
Restricted stock units issued	114,945

Investment in Rafael Pharmace_2

Investment in Rafael Pharmaceuticals (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2019	Sep. 19, 2017	Jul. 31, 2019
IDT-Rafael Holdings, LLC. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary			50.00%
Percentage of capital stock		10.00%
Exercise price of warrants or rights, description			Based on the current shares issued and outstanding of Rafael Pharmaceuticals as of October 1, 2019, we, and our affiliates would need to pay approximately $15 million to exercise the Warrant in full. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), we and our affiliates would need to pay approximately $45 million to exercise the Warrant to keep our ownership at 51%. On an as-converted fully diluted basis (for all convertible securities of Rafael Pharmaceuticals outstanding), we and our affiliates would need to pay approximately $70 million to exercise the Warrant in full. Howard Jonas holds 10% of the interest in IDT Rafael Holdings and would need to contribute 10% of any cash needed to exercise any portion of the Warrant.
Fully diluted			51.00%
Bonus shares			38.00%
IDT-Rafael Holdings, LLC. [Member] | Series D Convertible Preferred Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary			90.00%
Exercise of warrants purchases, description			The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distribute first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
Warrants expiry date			Dec. 31, 2020
Exercise price of warrants or rights, description			IDT-Rafael Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share.
Purchase of exercise the warrant, shares			16,700,000
IDT-Rafael Holdings, LLC. [Member] | Howard S. Jonas [Member] | Series C Convertible Notes [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Principal amount			$ 525
IDT-Rafael Holdings, LLC. [Member] | Howard Jonas and Deborah Jonas [Member] | Series C Convertible Notes [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Principal amount			$ 525
IDT-Rafael Holdings, LLC. [Member] | Howard Jonas [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary			10.00%
CS Pharma Holdings, LLC [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership percentage in non-operating subsidiary			50.00%
Ownership percentage in subsidiary and holds percentage of interest			90.00%
Indirect interest in assets held, percentage			45.00%
CS Pharma Holdings, LLC [Member] | Series D Convertible [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Convertible promissory note, rate of interest	3.50%
Principal amount	$ 10,000

Marketable Securities (Details)

Marketable Securities (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2018USD ($)
Available-for-sale securities:
Amortized Cost	$ 25,009
Gross Unrealized Gains	1
Gross Unrealized Losses	(40)
Fair Value	24,701
Municipal bonds [Member]
Available-for-sale securities:
Amortized Cost
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value
Federal Government Sponsored Enterprise notes [Member]
Available-for-sale securities:
Amortized Cost	2,837
Gross Unrealized Gains
Gross Unrealized Losses	(23)
Fair Value	2,814
International agency notes [Member]
Available-for-sale securities:
Amortized Cost	522
Gross Unrealized Gains
Gross Unrealized Losses	(17)
Fair Value	505
Corporate bonds [Member]
Available-for-sale securities:
Amortized Cost	2,948
Gross Unrealized Gains	1
Gross Unrealized Losses	(56)
Fair Value	2,893
U.S. Treasury notes [Member]
Available-for-sale securities:
Amortized Cost	5,476
Gross Unrealized Gains
Gross Unrealized Losses	(92)
Fair Value	5,384
Mutual Fund [Member]
Available-for-sale securities:
Amortized Cost	5,469
Gross Unrealized Gains
Gross Unrealized Losses	(98)
Fair Value	5,371
Certificates of deposit [Member]
Available-for-sale securities:
Amortized Cost	7,757	[1]
Gross Unrealized Gains		[1]
Gross Unrealized Losses	(23)	[1]
Fair Value	$ 7,734	[1]
[1]	Each of the Company's certificates of deposit has a CUSIP, was purchased in the secondary market through a broker, and may be sold in the secondary market.

Marketable Securities (Details

Marketable Securities (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Marketable Securities (Textual)
Proceeds from maturities and sales of available-for-sale securities	$ 25,000	$ 6,700
Net realized gain	$ 330	$ 12

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Available-for-sale securities:
Marketable Securities		$ 24,701
Hedge Funds	5,125	4,218
Rafael Pharmaceuticals convertible promissory notes		7,900
Total	5,125	36,819
Level 1 [Member]
Available-for-sale securities:
Marketable Securities		10,755
Hedge Funds
Rafael Pharmaceuticals convertible promissory notes
Total		10,755
Level 2 [Member]
Available-for-sale securities:
Marketable Securities		13,946
Hedge Funds
Rafael Pharmaceuticals convertible promissory notes
Total		13,946
Level 3 [Member]
Available-for-sale securities:
Marketable Securities
Hedge Funds	5,125	4,218
Rafael Pharmaceuticals convertible promissory notes		7,900
Total	$ 5,125	$ 12,118

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 1) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Balance, beginning of year	$ 12,118	$ 6,300
Contributions by former Parent at Spin-Off		3,949
Conversion of Rafael Pharmaceuticals Series D Convertible Note	(7,900)
Total gains included in earnings	907	1,869
Balance, end of year	$ 5,125	$ 12,118

Fair Value Measurements (Deta_3

Fair Value Measurements (Details Textual) $ in Thousands	Jul. 31, 2019USD ($)
Fair Value Measurements (Textual)
Spin-Off, IDT contribution investment amount	$ 2,000

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Receivables [Abstract]
Trade Accounts Receivable - Third Party	$ 561	$ 358
Trade Accounts Receivable - Related Party	11	11
Less Allowance for Doubtful Accounts	(122)	(82)
Trade Accounts Receivable, net	$ 450	$ 287

Trade Accounts Receivable (De_2

Trade Accounts Receivable (Details Textual) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Prepaid expenses and other current assets	$ 507	$ 421
Other assets	1,412	1,126
Noncurren Portion of Deferred Rental Income [Member]
Other assets	1,400	1,000
Curren Portion of Deferred Rental Income [Member]
Prepaid expenses and other current assets	$ 34	$ 88

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Property, Plant and Equipment [Abstract]
Building and Improvements	$ 54,241	$ 52,818
Land	10,412	10,412
Furniture and Fixtures	1,145	1,145
Other	255	255
Construction in Progress		1,024
Property and equipment, gross	66,053	65,654
Less Accumulated Depreciation	(17,320)	(15,541)
Total	$ 48,733	$ 50,113

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Property and Equipment (Textual)
Depreciation and amortization expense pertaining to property and equipment	$ 1,779	$ 1,698

Investment In LipoMedix Pharm_3

Investment In LipoMedix Pharmaceuticals Ltd. (Details) $ in Thousands	1 Months Ended
	Nov. 16, 2017USD ($)
Business Combinations [Abstract]
Other current assets	$ 16
Property and equipment, net	8
In Process Research and Development	1,575
Patents	155
Accounts payable	(85)
Accrued expenses	(22)
Net assets, excluding cash acquired and noncontrolling interest	1,647
Supplemental information:
Cash paid	2,400
Cash acquired	1,060
Cash paid, net of cash acquired	1,340
Historical loss on investment	(252)
Noncontrolling interest	559
Total consideration, net of cash acquired and noncontrolling interest	$ 1,647

Investment In LipoMedix Pharm_4

Investment In LipoMedix Pharmaceuticals Ltd. (Details Textual) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jul. 31, 2018	Nov. 16, 2017	Jul. 31, 2019	Jul. 31, 2018	Apr. 30, 2019
Investment In Lipomedix Pharmaceuticals Ltd. (“Lipomedix”) (Textual)
Description of acquisition entity			As a result of its initial $100,000 investment, the Company received approximately 3.2% of the common shares outstanding. During the second quarter of fiscal year 2017, the Company made an additional $300,000 investment in LipoMedix, increasing its ownership to 13.95% of the issued and outstanding ordinary shares, and provided LipoMedix with an additional advance of $200,000 against anticipated future equity investments. During the fourth quarter of fiscal year 2017, the Company made an additional $1.1 million investment, inclusive of the $200,000 advance, in LipoMedix, increasing its ownership to 38.86% of the issued and outstanding ordinary shares.
Selling, general, and administrative expense			$ 8,821	$ 5,519
LipoMedix [Member]
Investment In Lipomedix Pharmaceuticals Ltd. (“Lipomedix”) (Textual)
Issued and outstanding ordinary shares, percentage		50.60%
Initial investment		$ 100	$ 100
Description of acquisition entity	(i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the 2018 Bridge Note) (the "Financing"), the 2018 Bridge Note amount shall be converted into shares of LipoMedix of the same class and series with the same rights, preferences and privileges as shall be issued in the Financing at a conversion price per share equal to 75% or the lowest price per share paid by the investor(s) in the Financing; (ii) upon a Distribution Event (as defined in the Founder's Agreement among LipoMedix and certain of its founders), the 2018 Bridge Note shall be converted into shares of the most senior class of shares of LipoMedix then issued, at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the Distribution Event, or the Company shall be entitled to receive a redemption payment equal to the 2018 Bridge Note ($875,000); and (iii) if neither a Financing nor Distribution Event occurs prior to January 6, 2020 (18 months following the effective date of the 2018 Bridge Note), the 2018 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million, divided by its fully diluted share capital as of July 6, 2018).		(i) upon an issuance of an aggregate $2.0 million of additional equity securities (excluding the conversion of the Bridge Notes); or (ii) upon a liquidation or dissolution of LipoMedix or a sale of LipoMedix or its assets. If converted, the 2019 Bridge Note will be converted into shares of the most senior class of equity of LipoMedix then issued. If converted upon an equity financing, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the price paid in the equity offering. If converted upon a liquidation or sale event, the 2019 Bridge Note will be converted at a conversion price per share that is equal to 75% of the per share distribution received by LipoMedix equity holders in connection with the event, or, if greater the Company will receive a payment equal to the 2019 Bridge Note ($250,000). If none of such events occurs prior to September 28, 2019, the 2019 Bridge Note will be converted into the most senior class of shares LipoMedix has then issued at a conversion price per share equal to $0.53 (calculated on the basis of LipoMedix's pre-money valuation of $5.0 million).
No-interest bridge financing	$ 875			875	$ 250
Options exercised		$ 900
Noncontrolling Interest			$ 559	$ 559
Selling, general, and administrative expense			$ 440

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
Domestic	$ (3,410)	$ (2,581)
Foreign	(1,533)	(1,058)
Loss before Income Taxes	$ (4,943)	$ (3,639)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Current:
Foreign		$ 11
Federal
State
Total current expense		11
Deferred:
Foreign	(19)
Federal		8,219
State		207
Total deferred expense	(19)	8,426
Income tax expense	$ (19)	$ 8,437

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
U.S. federal income tax at statutory rate	$ (908)	$ (886)
State income tax	(172)	(141)
Valuation allowance	(30)	7,105
Foreign tax rate differential	(24)	(290)
Tax law change		2,499
Permanent differences	102	144
Rate Change	1,030
Other	(17)	6
Income tax expense	$ (19)	$ 8,437

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 5,316	$ 5,753
AMT carryforwards	2,692
Reserves and accruals	34	2,344
Stock-based compensation	119	14
Gross deferred tax assets	8,161	8,111
Less valuation allowance	(8,142)	(8,111)
Total deferred tax assets	19
Total deferred tax liabilities
Deferred tax assets, net	$ 19

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2018	Jul. 31, 2019
Income Taxes (Textual)
Federal statutory corporate tax, description		The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred ("transition tax"), and creates new taxes on certain foreign sourced earnings.
Federal and state net operating loss		$ 22,300
State net operating loss		3,200
Federal net operating loss		$ 1,200
Federal and state net operating loss, expiration date	Jul. 31, 2026	Jul. 31, 2038
U.S. federal statutory corporate tax rate	80.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Jul. 12, 2019	Sep. 17, 2018	Aug. 21, 2018
Commitments and Contingencies (Textual)
Settlement expenses			$ 100
Legal fees	$ 250,000
LipoMedix Pharmaceuticals Ltd. [Member]
Commitments and Contingencies (Textual)
Payment of consulting fees		$ 377
Consulting payments amounts			385
Other parties [Member]
Commitments and Contingencies (Textual)
Consulting payments amounts			$ 358

Convertible Note (Details)

Convertible Note (Details) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Debt Disclosure [Abstract]
Principal value of 6% convertible note at July 31, 2019, due November 15, 2021	$ 15,000
Debt discount	(54)
Total long-term carrying value of convertible note	$ 14,946

Convertible Note (Details Textu

Convertible Note (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2019	Apr. 30, 2019	Jul. 31, 2019
Convertible Note (Textual)
Interest expense on note	$ 667
Debt conversion converted, shares	1,849,749
At issuance [Member]
Convertible Note (Textual)
Debt discount to the beneficial conversion feature			$ 70
Amortized discount			16
Interest expense on note		$ 418	$ 650
Board of Directors Chairman [Member]
Convertible Note (Textual)
Convertible note, description			On November 15, 2018, Howard Jonas, the Company's Chairman, CEO, and controlling stockholder entered into an agreement to purchase a convertible note from the Company for $15.0 million. The term of the note was three years with interest accruing on the principal amount at a rate of 6% per annum, compounded quarterly. The note was subsequently assigned by Mr. Jonas to the Howard S. Jonas 2017 Annuity Trust. At the option of the Company, interest on the note can be capitalized and added to principal or payable in cash. The note was convertible at the option of the holder into shares of Class B common stock at a conversion price of $8.47 per share, the closing price of the Company's Class B common stock on the trading day before the date of the investment agreement. The initial principal amount of the note was convertible into 1,770,956 shares of Class B common stock, and if all interest for the three-year term of the note is capitalized, the note would have been convertible into 2,117,388 shares of Class B common stock. If the closing price of the Company's Class B common stock on the NYSE American is 200% of the conversion price for at least thirty (30) consecutive days, the Company had the right to cause conversion of the note.

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 23, 2019	Jan. 10, 2019	Nov. 05, 2018	Sep. 30, 2018	Apr. 26, 2018	Mar. 26, 2018	Jul. 31, 2019	Jul. 31, 2018	Nov. 15, 2018
Related Party Transactions (Textual)
Due to related parties
Due from related parties							280
Revenue received							2,125	$ 2,223
Cs Pharma Holdings [Member]
Related Party Transactions (Textual)
Ownership percentage description				In September 2018, CS Pharma, in which the Company owns an effective 45% interest, exercised a warrant to purchase 8 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock for $10 million representing approximately 8% of the equity on a fully-diluted basis (excluding the remainder of the warrant) of Rafael Pharmaceuticals. The warrant in full is exercisable for up to 56% of the fully diluted equity of Rafael Pharmaceuticals. The right to exercise the first $10 million of the warrant was held by CS Pharma. CS Pharma is owned by 0.25% by Michael Weiss, a non-employee director of the Company. The remainder of the warrant is held by IDT-Rafael Holdings, LLC.
Class B Common Stock [Member]
Related Party Transactions (Textual)
Purchase of Class B common stock shares					1,254,200
Closing price per share					$ 6.89
Aggregate purchase price					$ 8,641
Genie Energy, Ltd. [Member]
Related Party Transactions (Textual)
Due from related parties							$ 218
Ieases office space charge, description							The Company charges Genie $23.46 per square foot annually for approximately 8,631 square feet of space.
IDT Rafael Holdings, LLC [Member]
Related Party Transactions (Textual)
Warrant exercised	36,300,000	5,100,000	4,000,000
Proceeds from warrant exercises	$ 34,400	$ 6,400	$ 5,000
IDT [Member]
Related Party Transactions (Textual)
Due to related parties							$ 60
Due from related parties							8
Related party transaction, description						On March 26, 2018, IDT spun off the Company. In connection with the spin-off, IDT and the Company entered into a Transition Services Agreement, dated March 26, 2018 (the “TSA”), pursuant to which IDT, which is controlled by Howard S. Jonas and for which Howard S. Jonas serves as the Chairman of the Board, provides certain services to the Company. The services include, but are not limited to: administrative, tax and legal. IDT billed the Company approximately $390,000 under the TSA during Fiscal 2019 and approximately $60,000 for invoices paid by IDT on the Company’s behalf. In addition, during Fiscal 2019, the Company billed IDT approximately $64,000 for real estate advisory services provided to IDT, and approximately $25,000 for invoices paid by the Company on IDT’s behalf. IDT collected cash of approximately $174,000 on behalf of the Company, primarily from third parties who use the Company’s parking garage while the Company was in the process of changing its billing and collection systems.
Revenue received							$ 1,800
Ieases office space charge, description							Approximately 80,000 square feet of office space plus parking occupied by IDT at 520 Broad Street, Newark, NJ and approximately 3,600 square feet.
Ownership percentage description							IDT-Rafael Holdings, LLC, the Company's 90%-owned subsidiary and the remaining 10% of which is held by Howard Jonas, currently holds 36.7 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals. IDT-Rafael Holdings, LLC also owns 50% of CS Pharma Holdings, LLC ("CS Pharma"), a non-operating entity that holds 16.7 million shares of Rafael Pharmaceutical's Series D Convertible Preferred Stock.  The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 38% of the capital stock on a fully diluted basis (excluding the remainder of the warrant).
Rafael Pharmaceuticals, Inc. [Member]
Related Party Transactions (Textual)
Due from related parties							$ 480
Howard S. Jonas [Member]
Related Party Transactions (Textual)
Due to related parties	$ 3,400	$ 640	$ 500
Deposit amount								$ 864
Convertible debt									$ 15,000

Future Minimum Rents (Details)

Future Minimum Rents (Details) $ in Thousands	Jul. 31, 2019USD ($)
2020	$ 3,046
2021	3,177
2022	3,071
2023	2,747
2024	3,340
Thereafter	5,127
Total Minimum Future Rental Income	20,508
Related Parties [Member]
2020	1,992
2021	2,041
2022	2,078
2023	2,117
2024	2,155
Thereafter	1,659
Total Minimum Future Rental Income	12,042
Other [Member]
2020	1,054
2021	1,136
2022	993
2023	630
2024	1,185
Thereafter	3,468
Total Minimum Future Rental Income	$ 8,466

Future Minimum Rents (Details T

Future Minimum Rents (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Future Minimum Rents (Textual)
Net operating leases with initial term expiration dates	Dates ranging from 2021 to 2030.
Related party leases expire, description	The Company has related party leases that expire in April 2025, for (i) an aggregate of 88,631 square feet, and which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel.
Annual rent	$ 2,000
Related parties terminate leases, description	The related parties have the right to terminate the domestic leases upon four months' notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months' notice. IDT has the right to lease an additional 50,000 square feet, in 25,000 foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.
Revenue Benchmark [Member]
Future Minimum Rents (Textual)
Concentration risk percentage		10.00%
Related Parties [Member] | Revenue Benchmark [Member]
Future Minimum Rents (Textual)
Concentration risk percentage	53.00%	51.00%

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Segment Reporting Information [Line Items]
Revenues	$ 4,931	$ 4,371
Loss from operations	(6,696)	(3,841)
Real Estate [Member]
Segment Reporting Information [Line Items]
Revenues	4,931	4,371
Loss from operations	(5,083)	(2,780)
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Revenues
Loss from operations	$ (1,613)	$ (1,061)

Business Segment Information _2

Business Segment Information (Details 1)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Revenue Benchmark [Member]
Segment Reporting Information [Line Items]
Revenue from tenants located in Israel	3.00%	6.00%

Business Segment Information _3

Business Segment Information (Details 2) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Segment Reporting Information [Line Items]
Long-lived Assets, net	$ 48,733	$ 50,113
Total Assets	142,143	116,920
United States [Member]
Segment Reporting Information [Line Items]
Long-lived Assets, net	47,096	48,415
Total Assets	138,535	113,279
Israel [Member]
Segment Reporting Information [Line Items]
Long-lived Assets, net	1,637	1,698
Total Assets	$ 3,608	$ 3,641

Business Segment Information _4

Business Segment Information (Details Textual)	12 Months Ended
	Jul. 31, 2019Segments
Business Segment Information (Textual)
Number of operating segments	2

Equity (Details)

Equity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2019USD ($)$ / sharesshares
Equity [Abstract]
Number of Options, Outstanding, Beginning balance | shares | shares	626,662
Number of Options, Exercised | shares	(38,710)
Number of Options, Cancelled / Forfeited | shares | shares	(819)
Number of Options, OUTSTANDING, Ending balance | shares | shares	587,133
Number of Options, EXERCISABLE | shares | shares	572,934
Weighted-Average Exercise Price, Outstanding, Beginning balance | $ / shares | $ / shares	$ 4.90
Weighted-Average Exercise Price, Exercised | $ / shares | $ / shares	4.90
Weighted-Average Exercise Price, Cancelled / Forfeited | $ / shares | $ / shares	4.90
Weighted-Average Exercise Price, OUTSTANDING, Ending balance | $ / shares | $ / shares	4.90
Weighted-Average Exercise Price, EXERCISABLE | $ / shares | $ / shares	$ 4.90
Weighted-Average Remaining Contractual Term, OUTSTANDING	3 years 7 months 28 days
Weighted-Average Remaining Contractual Term, EXERCISABLE	3 years 7 months 28 days
Aggregate Intrinsic Value, OUTSTANDING | $ | $	$ 2,877
Aggregate Intrinsic Value, EXERCISABLE | $ | $	$ 2,807

Equity (Details 1)

Equity (Details 1)	12 Months Ended
	Jul. 31, 2019$ / sharesshares
Equity [Abstract]
Number of Non-vested Shares, Beginning Balance | shares	141,799
Number of Non-vested Shares, Granted | shares	74,637
Number of Non-vested Shares, Vested | shares	(60,010)
Number of Non-vested Shares, Cancelled / Forfeited | shares
Number of Non-vested Shares, Ending Balance | shares	156,426
Weighted- Average Grant- Date Fair Value, Beginning balance | $ / shares	$ 4.90
Weighted- Average Grant- Date Fair Value, Granted | $ / shares	16.49
Weighted- Average Grant- Date Fair Value, Vested | $ / shares	4.96
Weighted- Average Grant- Date Fair Value, Cancelled / Forfeited | $ / shares
Weighted- Average Grant- Date Fair Value, Ending balance | $ / shares	$ 10.41

Equity (Details Textual)

Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	Apr. 26, 2018	Mar. 31, 2018	Mar. 28, 2018	Mar. 26, 2018	Jul. 31, 2019	Jul. 31, 2018
Equity (Textual)
Total unrecognized non-vested stock-based compensation					$ 1,200
Stock options exercised price					$ 4.90
Option term, description					Option awards generally vest on a graded basis over five years of service and have ten-year contractual terms.
Total grant date fair value of shares vested					$ 298	$ 344
Non-vested stock options, weighted-average period					3 years
Number of options exercised					38,710
Number of options, cancelled shares					(819)
Number of restricted Shares, Granted					74,637
Fair value of restricted shares granted					$ 1,300
Employees [Member]
Equity (Textual)
Aggregate restricted shares issued				114,945
Common Stock, Series B
Equity (Textual)
Purchase of Class B common stock shares	1,254,200
Closing price per share	$ 6.89
Aggregate purchase price	$ 8,641
Number of options exercised					38,710
Number of options, cancelled shares					819
Number of restricted Shares, Granted					74,637
Common Stock, Series B | Maximum [Member]
Equity (Textual)
Vesting expected term					5 years
Common Stock, Series B | Minimum [Member]
Equity (Textual)
Vesting expected term					2 years
Common Stock, Series B | Employees [Member]
Equity (Textual)
Number of shares granted			76,445
Options, grants in period, grant date fair value			$ 375
Common Stock, Series B | IDT [Member]
Equity (Textual)
Aggregate restricted shares issued					92,690
2018 Equity Incentive Plan [Member]
Equity (Textual)
Share-based payment award, number of shares authorized		1,064,048
Options exercise price		$ 4.90
2018 Equity Incentive Plan [Member] | Common Stock, Series B
Equity (Textual)
Options issued		626,662
Officer [Member]
Equity (Textual)
Number of restricted Shares, Granted					70,718
Fair value of restricted shares granted					$ 1,200
Three non-employee directors [Member] | 2018 Equity Incentive Plan [Member]
Equity (Textual)
Aggregate restricted shares issued					4,203
Fair value of awards on date of grant included in selling, general and administrative expense					$ 107

Loss Per Share (Details)

Loss Per Share (Details) - shares	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Total	2,434,727	626,662
Convertible Note - Related Party [Member]
Total	1,847,594
Stock Options [Member]
Total	587,133	626,662